Targeting the Estrogen Receptor (ER) for the Treatment of Breast Cancer: Recent Advances and Challenges
University of Michigan Library · 01.01.2023
DOI: 10.7302/7864 ↗Kurz gefasst
Fachartikel in der Zeitschrift University of Michigan Library, erschienen am 01.01.2023. Verfasst von Rohan Kalyan Rej und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Estrogen receptor alpha (ERα) is a well-established therapeutic target for the treatment of ER-positive (ER+) breast cancers. Despite the tremendous successes achieved by tamoxifen, a selective estrogen receptor modulator, and aromatase inhibitors (AIs), resistance to these therapies is a major clinical problem. Therefore, induced protein degradation and covalent inhibition have been pursued as new therapeutic approaches to target ERα. This review summarizes recent progress in the discovery and development of oral selective ER degraders (SERDs), CERANs (complete estrogen receptor antagonists), SERCAs (selective estrogen receptor covalent antagonists), and PROTAC (proteolysis targeting chimera) ER degraders. We focus on those compounds which have been advanced into clinical development
Schlagwörter
Zitieren
APA
Rej, R. K., II, T., Eugene, J., Acharyya, R. K., Rae, J. M., & Wang, S. (2023). Targeting the Estrogen Receptor (ER) for the Treatment of Breast Cancer: Recent Advances and Challenges. University of Michigan Library. https://doi.org/10.7302/7864
Vancouver
Rej RK, II T, Eugene J, Acharyya RK, Rae JM, Wang S. Targeting the Estrogen Receptor (ER) for the Treatment of Breast Cancer: Recent Advances and Challenges. University of Michigan Library. 2023. doi:10.7302/7864
BibTeX
@article{Rej2023,
author = {Rej, Rohan Kalyan and II, Thomas and Eugene, Junius and Acharyya, Ranjan Kumar and Rae, James Michael and Wang, Shaomeng},
title = {Targeting the Estrogen Receptor (ER) for the Treatment of Breast Cancer: Recent Advances and Challenges},
journal = {University of Michigan Library},
year = {2023},
doi = {10.7302/7864}
}
EUVIMED